Table 2.
Psychophysiological measures.
| Scan | Measure | Controls | PMQ-H | PMQ-L | F | p |
|---|---|---|---|---|---|---|
| Baseline scan | ||||||
| [11C]-carfentanil injected dose (mCi) | 15.9 ± 0.5 | 15.4 ± 0.6 | 15.7 ± 0.4 | 2.98 | 0.06 | |
| [11C]-carfentanil mass injected (μg/kg) | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.005 | 0.48 | 0.62 | |
| PANAS positive | 32.5 ± 6.6 | 29.5 ± 6.9 | 27.7 ± 9.2 | 1.45 | 0.25 | |
| PANAS negative | 11.5 ± 2.0 | 15.0 ± 3.6 | 14.1 ± 5.5 | 3.05 | 0.06 | |
| POMS-TMD | −3.0 ± 10.2 | 23.8 ± 19.7 | 15.9 ± 18.9 | 9.76 | <0.001 | |
| Pain scan | ||||||
| [11C]-carfentanil injected dose (mCi) | 15.4 ± 0.5 | 15.4 ± 1.2 | 15.6 ± 0.4 | 0.36 | 0.70 | |
| [11C]-carfentanil mass injected (μg/kg) | 0.02 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.89 | 0.42 | |
| ΔPANAS positive | 8.8 ± 7.7 | 3.7 ± 3.0 | 5.3 ± 10.3 | 1.36 | 0.27 | |
| ΔPANAS negative | 0.4 ± 1.9 | 0.9 ± 3.0 | −1.2 ± 8.5 | 0.52 | 0.60 | |
| ΔPOMS-TMD | −8.4 ± 11.3 | 8.8 ± 16.4 | −0.4 ± 21.5 | 3.02 | 0.06 | |
| Pain intensity | 30.2 ± 17.0 | 42.73 ± 13.9 | 43.9 ± 23.0 | 2.16 | 0.13 | |
| Pain unpleasantness | 35.8 ± 30.5 | 46.4 ± 26.1 | 45.0 ± 24.4 | 0.57 | 0.57 | |
| MPQ sensory | 17.8 ± 8.0 | 16.2 ± 7.4 | 18.9 ± 7.7 | 0.39 | 0.68 | |
| MPQ affective | 1.5 ± 2.1 | 1.8 ± 2.8 | 1.9 ± 2.2 | 0.11 | 0.89 | |
| Average 15-sec VAS | 26.1 ± 13.5 | 39.5 ± 10.3 | 32.6 ± 16.3 | 2.79 | 0.08 | |
Mean ± 1 SD of psychophysical measure of pain during the pain-stress challenge. VAS intensity refers to the average ratings of momentary pain acquired every 15 s for the duration of the pain-stress challenge (20 min). The remainder of the scales (MPQ; PANAS; and POMS-TMD) were obtained immediately after completion of the pain-stress challenge.